{'fraction_non_alphanumeric': 0.043401240035429584, 'fraction_numerical': 0.048715677590788306, 'mean_word_length': 4.512195121951219, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Role of High VWF and Low ADAMTS-13 in Ischemic Stroke

Aim: To measure levels of VWF and ADAMTS-13 in patients of ischemic stroke and healthy controls. Method: Blood samples of forty five patients and forty five controls of age 30-65 years were taken from medical or neurology wards of Lahore General Hospital. VWF antigen assay was determined by Immuno-Turbidimetric method and quantitative ADAMTS-13 antigen assay was measured by ELISA. Results: The mean level of plasma VWF antigen of controls was 114.0±49.7% and mean plasma level of VWF antigen in patients was 137.0±54.3%. The mean plasma VWF antigen level was significantly elevated among patients as compared to controls (p=0.011). The mean ADAMTS-13 antigen level of controls was 151.7± 87.9 U/L and mean ADAMTS-13 antigen level of patients was 107.9±106.7 U/L. Our study also found that mean ADAMTS-13 was significantly lower in patients as compared to controls (p=0.018). Conclusion: In conclusion, Vwf and ADAMTS-13 antigen assays have an important role in pathogenesis of clot formation in patients of ischemic stroke. Keywords: Low ADAMTS, ischemic stroke, high WWF